Evidence map›Paper›PMID 33118614›Full record

Observational studyBritish journal of haematology2021

Effect of initial treatment on health-related quality of life in patients with newly diagnosed multiple myeloma without immediate stem cell transplant intent: results from the Connect

Rafat Abonour, Robert M Rifkin, Cristina Gasparetto, Kathleen Toomey, Brian G M Durie, James W Hardin, Howard R Terebelo, Sundar Jagannath, Mohit Narang, Sikander Ailawadhi and 7 more

Registry-linked trialOpen access · hybridAbstract readMulticenter StudyObservational Study
PubMed Full text at PMC Publisher
In one paragraph

Observational study in British journal of haematology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT01081028 (Connect® MM- The Multiple Myeloma Disease Registry), which is not on this map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.5field-weighted citation impact, top 31% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT01081028 terminatednot on this map

Connect® MM- The Multiple Myeloma Disease Registry

Typeobservational_patient_registrySponsorCelgeneRan2009 to 2024Enrolled3,011ConditionsMultiple MyelomaArmsFirst-line therapy, Second-line Multiple Myeloma treatments
3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 8 citations in OpenAlex.

  1. Review
  2. Article
  3. Observational
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors at 12 institutions in 1 country.

Rafat AbonourIndiana University, Indianapolis, IN, USA.ORCID 0000-0003-1491-2548
Robert M RifkinRocky Mountain Cancer Centers US Oncology, Denver, CO, USA.ORCID 0000-0003-3141-1518
Cristina GasparettoDuke University Medical Center, Durham, NC, USA.
Kathleen ToomeySteeplechase Cancer Center, Somerville, NJ, USA.
Brian G M DurieCedars-Sinai Medical Center, Los Angeles, CA, USA.
James W HardinUniversity of South Carolina, Columbia, SC, USA.
Howard R TerebeloProvidence Cancer Institute, Southfield, MI, USA.ORCID 0000-0002-4208-2353
Sundar JagannathMount Sinai Hospital, New York, NY, USA.
Mohit NarangUS Oncology Research, Columbia, MD, USA.
Sikander AilawadhiMayo Clinic, Jacksonville, FL, USA.ORCID 0000-0002-8377-8111
James L OmelMyeloma Research Advocate/Advisor, Grand Island, NE, USA.
Hans C LeeThe University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Shankar SrinivasanBristol Myers Squibb, Princeton, NJ, USA.
Amani KitaliBristol Myers Squibb, Princeton, NJ, USA.
Amit AgarwalBristol Myers Squibb, Princeton, NJ, USA.
Lynne WagnerWake Forest School of Medicine, Winston-Salem, NC, USA.
CONNECT MM Registry Investigators
Bristol-Myers Squibb (United States) · USCedars-Sinai Medical Center · USDuke Medical Center · USIndiana University Indianapolis · USJacksonville College · USMount Sinai Hospital · USProvidence Hospital · USRocky Mountain Cancer Centers · USSomerville Hospital · USThe University of Texas MD Anderson Cancer Center · USUniversity of South Carolina · USWake Forest University · US

Funding

Celgene Corporation and Bristol Myers Squibb
6 · The paper itself

Abstract

Although new multiple myeloma (MM) therapies are effective in alleviating some disease-associated symptoms (e.g. bone pain, fatigue, functional decline), they can result in additional toxicities, further impacting health-related quality of life (HRQoL). Here, we compared HRQoL and safety of lenalidomide-bortezomib-dexamethasone [RVd (n = 445)], bortezomib-melphalan-prednisone [VMP (n = 77)] and Vd or VMP (n = 588) in patients with newly diagnosed MM (NDMM) from the Connect

Indexed as

AdultAgedAged, 80 and overAngiogenesis InhibitorsAntineoplastic AgentsAntineoplastic Agents, AlkylatingAntineoplastic Agents, HormonalAntineoplastic Combined Chemotherapy ProtocolsBortezomibCase-Control StudiesDexamethasoneFemaleHumansLenalidomideMaleMelphalanAngiogenesis InhibitorsAntineoplastic AgentsAntineoplastic Agents, AlkylatingAntineoplastic Agents, HormonalBortezomibDexamethasoneLenalidomideMelphalanPrednisonehealth-related quality of lifelenalidomidemultiple myelomareal-world evidence

Identifiers

PMID33118614
PMCPMC8048460
OpenAlexW3097766035

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.